Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Eckard Kujath has worked on the following 6 EPO patent applications which have been published in the last five years:

EP12756214

SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS

IPC classification:
A61K 31/427, A61P 9/06, A61P 9/10, C07D 417/12, C07D 417/14, C07D 471/04, C07D 487/04
Applicant:
Sanofi, S.A.
Agent:
Eckard Kujath, Sanofi-Aventis Deutschland GmbH
Agent:
Paula De Souza, Sanofi
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12759725

N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

IPC classification:
A61K 31/4985, A61P 19/02, C07D 487/04
Applicant:
Sanofi, S.A.
Agent:
Multiple attorneys, Sanofi-Aventis Deutschland GmbH
Status:
GRANT OF PATENT INTENDED
EP11306128

Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals

IPC classification:
A61K 31/427, A61P 9/06, A61P 9/10, C07D 417/12, C07D 417/14, C07D 471/04, C07D 487/04
Applicant:
Sanofi, S.A.
Agent:
Eckard Kujath, Sanofi-Aventis Deutschland GmbH
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14710222

SUBSTITUTED CHROMAN-6-YLOXY-CYCLOALKANES AND THEIR USE AS PHARMACEUTICALS

IPC classification:
A61K 31/353, A61P 9/00, C07D 311/60, C07D 405/12, C07D 407/12, C07D 407/14, C07D 409/12, C07D 413/12, C07D 417/12, C07D 417/14, C07F 9/09
Applicant:
Sanofi, S.A.
Agent:
Eckard Kujath, Sanofi-Aventis Deutschland GmbH
Agent:
Paula De Souza, Sanofi
Status:
PATENT GRANTED
EP14711467

N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS

IPC classification:
A61K 31/437, A61K 31/52, A61P 9/00, A61P 19/02, C07D 471/04, C07D 487/04
Applicant:
Sanofi, S.A.
Agent:
Multiple attorneys, Sanofi-Aventis Deutschland GmbH
Status:
PATENT GRANTED
EP11306179

N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals

IPC classification:
A61K 31/4985, A61P 19/02, C07D 487/04
Applicant:
Sanofi, S.A.
Agent:
Eckard Kujath, Sanofi-Aventis Deutschland GmbH
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT

Please Sign in to use this feature